Abstract 416P
Background
Head and neck cancer is one of the most common malignancies in India, with the highest incidence worldwide. Our aim was to study head and neck sarcomas- tumor types, their treatment strategies, recurrence patterns and survival in patients treated in a tertiary centre in the densely populated Northern India.
Methods
This is a retrospective study of a prospectively maintained database. Patients treated between January 2011- June 2016 at the centre were included. Surgical treatment was wide excision (aim was to get disease free margins within the restrictions of the region). Chemotherapy was mainly doxorubicin-based with drugs like cisplatin, ifosfamide, etoposide, vincristine and cyclophosfamide added as per the histology. Radiotherapy was given as part of the curative treatment in Ewing’s sarcoma. Adjuvant radiation therapy was given in close/involved margins or locally advanced disease in other histologies. Patients with distant or locally advanced disease underwent multimodal management.
Results
The study included 29 cases. Histologies were varied, with the most common type being osteosarcoma, followed by chondrosarcoma. Ewing’s sarcoma, pleomorphic sarcoma and spindle cell sarcoma were the other common types. Most common site of involvement was mandible. Surgery was done in 68.9% (n = 20). High grade disease was seen in 22 patients (75.9%). Margins were clear in 17 patients (80.9%); close margins were documented in 4 patients (19%). Locoregional and distant recurrences occurred in 15% (n = 3) & 10% (n = 2), respectively. Factors affecting the risk of recurrence are high grade, close margins and locally advanced disease. However there is no influence of size, grade or margin status on survival. Median survival was 33 months. The 3 year disease free survival was 52% (95% CI- 0.44-0.83).
Conclusions
Head and neck sarcoma is a rare heterogeneous group in one of the commonest sites of malignancy in India. Apart from appropriate identification of the cases, the better chance of survival is provided by an expert unit with multidisciplinary management, and chance of surgical salvage in case of recurrence.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract